title: Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.
abstract: BACKGROUND
  Hormone receptor status and HER2 status are of critical interest in determining the prognosis of breast cancer patients. Their status is routinely assessed by immunohistochemistry (IHC). However, it is subject to intra-laboratory and inter-laboratory variability. The aim of our study was to compare the estrogen receptor, progesterone receptor and HER2 status as determined by the MapQuant™ test to the routine immuno-histochemical tests in early stage invasive breast cancer in a large comprehensive cancer center.
  
  
  METHODS
  We retrospectively studied 163 invasive early-stage breast carcinoma with standard IHC status. The genomic status was determined using the MapQuant™ test providing the genomic grade index.
  
  
  RESULTS
  We found only 4 tumours out of 161 (2.5%) with discrepant IHC and genomic results concerning ER status. The concordance rate between the two methods was 97.5% and the Cohen's Kappa coefficient was 0.89. Comparison between the MapQuant™ PR status and the PR IHC status gave more discrepancies. The concordance rate between the two methods was 91.4% and the Cohen's Kappa coefficient was 0.74. The HER2 MapQuant™ test was classified as « undetermined » in 2 out of 163 cases (1.2%). One HER2 IHC-negative tumour was found positive with a high HER2 MapQuant™ genomic score. The concordance rate between the two methods was 99.3% and the Cohen's Kappa coefficient was 0.86.
  
  
  CONCLUSIONS
  Our results show that the MapQuant™ assay, based on mRNA expression assay, provides an objective and quantitative assessment of Estrogen receptor, Progesterone receptor and HER2 status in invasive breast cancer.
authors.affiliation: Department of Surgery, Institut Curie, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Mouttet
authors.affiliation: Department of Tumor Biology, Institut Curie, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Laé
authors.affiliation: Department of Tumor Biology, Institut Curie, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Caly
authors.affiliation: Department of Translational Research, Institut Curie, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Gentien
authors.affiliation: QIAGEN Marseille SA, Marseille, France.
authors.forename: S
authors.initials: S
authors.lastname: Carpentier
authors.affiliation: QIAGEN Marseille SA, Marseille, France.
authors.forename: H
authors.initials: H
authors.lastname: Peyro-Saint-Paul
authors.affiliation: Department of Tumor Biology, Institut Curie, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Vincent-Salomon
authors.affiliation: Department of Surgery, Institut Curie, Paris, France.
authors.forename: R
authors.initials: R
authors.lastname: Rouzier
authors.affiliation: Department of Tumor Biology, Institut Curie, Paris, France.
authors.forename: B
authors.initials: B
authors.lastname: Sigal-Zafrani
authors.affiliation: Department of Tumor Biology, Institut Curie, Paris, France.
authors.forename: X
authors.initials: X
authors.lastname: Sastre-Garau
authors.affiliation: Department of Surgery, Institut Curie, Paris, France.|Residual Tumor and Response to Treatment Team, Institut Curie, Department of Translational Research, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Reyal
mesh_terms: D000328:Adult; D000368:Aged; D001681:Biological Assay; D001943:Breast Neoplasms / Q000145:classification / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000066491:Clinical Decision-Making; D005260:Female; D015894:Genome, Human; D006801:Humans; D007150:Immunohistochemistry; D046228:Microarray Analysis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
references.citation: Acta Oncol. 2003;42(1):43-7
references.pmid: 12665330
references.citation: PLoS One. 2012;7(4):e35184
references.pmid: 22529987
references.citation: Pharmacogenomics. 2007 Jan;8(1):101-11
references.pmid: 17187513
references.citation: J Clin Oncol. 2012 Nov 1;30(31):3792-9
references.pmid: 22987084
references.citation: Crit Rev Oncol Hematol. 2011 Jan;77(1):20-9
references.pmid: 20138540
references.citation: Am J Clin Pathol. 2007 Mar;127(3):356-65
references.pmid: 17276950
references.citation: Oncologist. 2008 May;13(5):477-93
references.pmid: 18515733
references.citation: Clin Cancer Res. 2009 Nov 15;15(22):7003-11
references.pmid: 19887485
references.citation: Evid Rep Technol Assess (Full Rep). 2007 Dec;(160):1-105
references.pmid: 18457476
references.citation: J Clin Oncol. 2008 May 20;26(15):2433-5
references.pmid: 18487563
references.citation: Ann Pathol. 2010 Oct;30(5):357-73
references.pmid: 21055523
references.citation: Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8
references.pmid: 18159035
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3846-52
references.pmid: 17679725
references.citation: Breast Cancer Res. 2008;10(4):R65
references.pmid: 18662380
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4279-85
references.pmid: 21990395
references.citation: J Natl Cancer Inst. 2002 Jun 5;94(11):852-4
references.pmid: 12048273
references.citation: J Clin Pathol. 2000 Feb;53(2):125-30
references.pmid: 10767828
references.citation: Indian J Med Sci. 2009 Jan;63(1):21-7
references.pmid: 19346635
references.citation: Ann Intern Med. 2008 Mar 4;148(5):358-69
references.pmid: 18252678
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3185-91
references.pmid: 19364972
references.citation: BMC Genomics. 2008;9:394
references.pmid: 18717985
references.citation: J Clin Oncol. 2010 Oct 1;28(28):4300-6
references.pmid: 20697093
references.citation: Eur J Cancer. 2006 Nov;42(17):2946-53
references.pmid: 16989997
references.citation: Lancet Oncol. 2007 Mar;8(3):203-11
references.pmid: 17329190
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3032-8
references.pmid: 16809727
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1239-46
references.pmid: 17401012
references.citation: Breast. 2011 Oct;20 Suppl 3:S87-91
references.pmid: 22015300
references.citation: Patholog Res Int. 2011;2011:890938
references.pmid: 21845210
references.citation: Clin Breast Cancer. 2006 Jun;7(2):153-7
references.pmid: 16800975
references.citation: Cancer. 2011 Feb 1;117(3):472-9
references.pmid: 20878674
references.citation: Pathobiology. 2008;75(2):104-11
references.pmid: 18544965
references.citation: J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
references.pmid: 16478745
references.citation: J Clin Oncol. 2008 May 20;26(15):2473-81
references.pmid: 18487567